Ionis Pharmaceuticals, Inc 近日迎来重大利好消息。根据最新合作协议条款，该公司已具备资格获取一笔高达1500万美元的里程碑付款。更值得关注的是，其特许权使用费结构将采用分层模式，最高可达产品净销售额的30%。
这一商业安排凸显了Ionis Pharmaceuticals核心产品的市场潜力。分层特许权使用费机制通常基于销售额达成特定门槛后触发更高费率，最高30%的比例在生物制药行业属于极具竞争力的商业条款。里程碑付款与销售分成的组合方案，既体现了合作伙伴对产品商业前景的信心，也为Ionis Pharmaceuticals提供了持续的收入增长动力。
当前，生物技术公司越来越依赖此类创新商业模式来最大化产品价值。对于Ionis Pharmaceuticals而言，这笔潜在收益将为其研发管线注入新的资金支持，同时强化公司在罕见病和精准医疗领域的战略布局。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.